Related Experiment Video
Updated: Sep 30, 2025
A TIRF Microscopy Technique for Real-time, Simultaneous Imaging of the TCR and its Associated Signaling Proteins
Published on: March 22, 2012
Seven mysteries of LAG-3: a multi-faceted immune receptor of increasing complexity
Stephanie E A Burnell1, Lorenzo Capitani1, Bruce J MacLachlan1
1Division of Infection and Immunity, Henry Wellcome Building, Cardiff University, Cardiff, UK.
Abstract:
Despite three decades of research to its name and increasing interest in immunotherapies that target it, LAG-3 remains an elusive co-inhibitory receptor in comparison to the well-established PD-1 and CTLA-4. As such, LAG-3 targeting therapies have yet to achieve the clinical success of therapies targeting other checkpoints. This could, in part, be attributed to the many unanswered questions that remain regarding LAG-3 biology. Of these, we address: (i) the function of the many LAG-3-ligand interactions, (ii) the hurdles that remain to acquire a high-resolution structure of LAG-3, (iii) the under-studied LAG-3 signal transduction mechanism, (iv) the elusive soluble form of LAG-3, (v) the implications of the lack of (significant) phenotype of LAG-3 knockout mice, (vi) the reports of LAG-3 expression on the epithelium, and (vii) the conflicting reports of LAG-3 expression (and potential contributions to pathology) in the brain. These mysteries which surround LAG-3 highlight how the ever-evolving study of its biology continues to reveal ever-increasing complexity in its role as an immune receptor. Importantly, answering the questions which shroud LAG-3 in mystery will allow the maximum therapeutic benefit of LAG-3 targeting immunotherapies in cancer, autoimmunity and beyond.
Insights
Lymphocyte-activation gene 3 (LAG-3) is an elusive immune checkpoint receptor. Understanding LAG-3"s complex biology is crucial for developing effective immunotherapies for cancer and autoimmunity.
Area of Science:
- Immunology
- Molecular Biology
- Cancer Research
Background:
- Lymphocyte-activation gene 3 (LAG-3) is a co-inhibitory immune receptor, yet its biology remains less understood than PD-1 and CTLA-4.
- LAG-3 targeting immunotherapies show promise but have not yet matched the clinical success of other checkpoint inhibitors.
- Unanswered questions regarding LAG-3 biology hinder the full therapeutic potential of LAG-3 targeting agents.
Purpose of the Study:
- To address key unanswered questions in LAG-3 biology.
- To elucidate the function of LAG-3-ligand interactions.
- To explore the structural, signaling, and expression complexities of LAG-3.
Main Methods:
- Review and synthesis of existing research on LAG-3.
- Analysis of structural biology challenges related to LAG-3.
- Investigation of LAG-3 signal transduction pathways.
- Examination of soluble LAG-3 forms and knockout mouse models.
- Evaluation of LAG-3 expression in epithelial tissues and the brain.
Main Results:
- Multiple LAG-3-ligand interactions require further functional characterization.
- Acquiring high-resolution LAG-3 structures presents significant hurdles.
- LAG-3 signaling mechanisms are not fully understood.
- The soluble form of LAG-3 and its functions are elusive.
- LAG-3 knockout mice exhibit minimal phenotypic changes, complicating functional assessment.
- LAG-3 expression on epithelium and in the brain shows conflicting reports and requires further investigation.
Conclusions:
- The complex and evolving understanding of LAG-3 biology necessitates further research.
- Resolving the mysteries surrounding LAG-3 will optimize its therapeutic applications in cancer and autoimmune diseases.
- Future studies should focus on clarifying LAG-3-ligand interactions, structure, signaling, and expression patterns to maximize immunotherapy benefits.
Related Concept Videos
01:28Diversity of Antigen Receptors
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
01:24B Cell Activation and Differentiation
When naive B cells encounter a specific antigen that can bind to the B cell receptor (BCR) on their surface, they undergo sensitization to respond to the antigen's presence. Sensitization begins with...
01:31Immunoglobulin-like Cell Adhesion Molecules
Ig-CAMs exhibit either homophilic binding (to other Ig-CAMs) or heterophilic binding (to other ligands such as integrins). While most Ig-CAMs...
01:57Protein Complexes with Interchangeable Parts
The SCF ubiquitin ligase is a protein complex of five individual proteins. This complex attaches ubiquitin to other target proteins to mark them for degradation. In order...
01:30Assembly of Signaling Complexes
Interaction domains in cell signaling
Interaction domains recognize exposed features of their binding partners containing post-translationally modified sequences,...
01:22T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...